Royalty Pharma plc logo
Royalty Pharma plc RPRX
$ 45.36 -0.37%

Annual report 2025
added 02-11-2026

report update icon

Royalty Pharma plc Balance Sheet 2011-2026 | RPRX

Annual Balance Sheet Royalty Pharma plc

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

5.41 B 5.56 B 4.81 B 5.95 B 4.6 B - - - - - - -

Long Term Debt

8.57 B 6.61 B 6.14 B 6.12 B 7.1 B 5.82 B 5.96 B 6.24 B - - - - - - -

Long Term Debt Current

380 M 998 M - 998 M - - - - - - - - - - -

Total Non Current Liabilities

- - - - - - 5.98 B 6.24 B - - - - - - -

Total Current Liabilities

636 M 1.25 B 161 M 1.17 B 171 M 308 M - - - - - - - - -

Total Liabilities

9.91 B 7.88 B 6.3 B 7.29 B 7.27 B 6.12 B 6.31 B 6.82 B - - - - - - -

Retained Earnings

2.36 B 2.85 B 2.52 B 1.96 B 2.26 B 1.92 B 2.83 B 1.22 B - - - - - - -

Total Assets

19.6 B 18.2 B 16.4 B 16.8 B 17.5 B 16 B 12.4 B 11.4 B - - - - - - -

Cash and Cash Equivalents

619 M 929 M 477 M 1.71 B 1.54 B 1.01 B 246 M 1.92 B - - - - - - -

Book Value

9.71 B 10.3 B 10.1 B 9.53 B 10.2 B 9.9 B 6.14 B 4.55 B - - - - - - -

Total Shareholders Equity

9.71 B 10.3 B 10.1 B 9.53 B 10.2 B 9.9 B 6.14 B 4.55 B - - - - - - -

All numbers in USD currency

Quarterly Balance Sheet Royalty Pharma plc

2025-Q3 2025-Q2 2025-Q1 2024-Q3 2024-Q2 2024-Q1 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

8.57 B 7 B 6.62 B 6.61 B 7.6 B - 6.13 B 6.13 B 6.12 B 6.12 B 6.11 B - 7.1 B 7.1 B 7.09 B 5.83 B 5.82 B 5.82 B 5.82 B 5.82 B 5.82 B 5.96 B 5.96 B 5.96 B - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

9.73 B 8.82 B 7.82 B 7.78 B 7.9 B - 6.27 B 7.31 B 7.25 B 7.29 B 7.26 B - 7.24 B 7.27 B 7.35 B 6.11 B 6.08 B 6.12 B 6.12 B 6.12 B 6.12 B 6.31 B 6.31 B 6.31 B - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

2.3 B 2.22 B 2.48 B 2.76 B 2.38 B - 2.13 B 2.25 B 2.22 B 1.96 B 2.5 B - 2.22 B 2.26 B 2.32 B 2.29 B 1.92 B 1.92 B 1.92 B 1.92 B 1.92 B 2.83 B 2.83 B 2.83 B - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

19.3 B 18.3 B 17.6 B 18 B 17.7 B - 15.9 B 17.1 B 17.1 B 16.8 B 17.7 B - 17.4 B 17.5 B 17.7 B 16.5 B 15.9 B 16 B 16 B 16 B 16 B 12.4 B 12.4 B 12.4 B - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

939 M 632 M 1.09 B 950 M 1.76 B 843 M 936 M 2.17 B 1.98 B 1.71 B 992 M 2.11 B 1.79 B 1.54 B 1.8 B 1.14 B 709 M 1.01 B 1.01 B 1.01 B 1.01 B 246 M 246 M 284 M - 1.92 B - - - 1.38 B - - - - - - - - - - - - - - - - - - - - - - - - - - -

Book Value

9.62 B 9.5 B 9.79 B 10.3 B 9.75 B - 9.59 B 9.81 B 9.82 B 9.53 B 10.4 B - 10.1 B 10.2 B 10.4 B 10.4 B 9.84 B 9.9 B 9.9 B 9.9 B 9.9 B 6.14 B 6.14 B 6.14 B - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

9.62 B 9.5 B 9.79 B 10.3 B 9.75 B 9.86 B 9.59 B 9.81 B 9.82 B 9.53 B 10.4 B 10.4 B 10.1 B 10.2 B 10.4 B 10.4 B 9.84 B 9.9 B 9.9 B 9.9 B 9.9 B 6.14 B 6.14 B 6.14 B 4.71 B 4.55 B - - - 4.46 B - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Royalty Pharma plc, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
Benitec Biopharma Benitec Biopharma
BNTC
$ 10.98 -4.52 % $ 452 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 221.88 -0.87 % $ 5 B danmarkDanmark
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Milestone Pharmaceuticals Milestone Pharmaceuticals
MIST
$ 1.36 -20.0 % $ 45.5 M canadaCanada
Pharming Group N.V. Pharming Group N.V.
PHAR
$ 15.36 -0.71 % $ 7.59 B niderlandNiderland
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Inventiva S.A. Inventiva S.A.
IVA
$ 5.78 -4.3 % $ 138 M franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Tiziana Life Sciences PLC Tiziana Life Sciences PLC
TLSA
$ 1.21 -3.97 % $ 71.5 M britainBritain
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
PainReform Ltd. PainReform Ltd.
PRFX
$ 2.28 -0.44 % $ 1.03 M israelIsrael
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Assembly Biosciences Assembly Biosciences
ASMB
$ 28.46 3.45 % $ 319 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.37 -4.2 % $ 350 M britainBritain
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 156.92 -1.23 % $ 7.81 B usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.4 -3.68 % $ 1.02 B canadaCanada
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 54.13 -1.64 % $ 10.4 B usaUSA
Calithera Biosciences Calithera Biosciences
CALA
- -10.95 % $ 876 K usaUSA
Cara Therapeutics Cara Therapeutics
CARA
- -3.03 % $ 260 M usaUSA
ChemoCentryx ChemoCentryx
CCXI
- - $ 3.74 B usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
Compugen Ltd. Compugen Ltd.
CGEN
$ 2.09 -0.95 % $ 195 M israelIsrael
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.52 -5.59 % $ 178 M usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
- - $ 169 M usaUSA
Clovis Oncology Clovis Oncology
CLVS
- -7.23 % $ 13 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Burford Capital Limited Burford Capital Limited
BUR
$ 7.7 -5.87 % $ 1.29 B britainBritain
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
$ 8.6 -3.8 % $ 115 M usaUSA
Curis Curis
CRIS
$ 0.77 1.89 % $ 4.86 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA